Johnson & Johnson 10-Qquarter ended 2026-09-27

Executive Summary

Johnson & Johnson earns revenue by selling prescription medicines and medical devices to healthcare providers and patients worldwide. Its growth is increasingly driven by oncology, neuroscience and newer immunology medicines, while the planned Orthopaedics separation will reshape MedTech. Q3 sales rose 5.9% to $25.4B as newer medicines more than offset STELARA’s decline following biosimilar competition. Earnings nearly disappeared after a $5.5B proposed talc-settlement charge, while acquired research, impairments and separation costs also reduced segment profits. For investors, the opportunity is continued growth from newer treatments and devices; the challenge is converting that growth into earnings and cash after patent losses, investment and litigation payments.

What's Happening in the Business

• Medicines are replacing lost exclusivity revenue. Oncology sales grew 16%, supported by DARZALEX, CARVYKTI, TECVAYLI, TALVEY and RYBREVANT/LAZCLUZE. SPRAVATO and CAPLYTA drove neuroscience growth. TREMFYA sales increased 68% to $2.40B, but immunology grew only 1.3% because STELARA sales fell 54%. STELARA alone reduced companywide operational growth by ≈4.2 percentage points.

• MedTech’s growth was uneven. Electrophysiology and Shockwave adoption supported cardiovascular sales, while lower Abiomed patient volumes offset some gains. Surgery declined amid China procurement pressure, competition and Middle East disruption. Orthopaedics benefited from launches and VELYS-related demand, but management targets its separation for mid-2027, changing the portfolio rather than simply cutting costs.

• Pipeline investment weighed on current profits. Firefly Bio generated ≈$1.0B of acquired in-process R&D expense. Initial Sail Biomedicines payments totaled $800M, including a $500M equity investment and a $300M option premium. These investments add development opportunities, not established product revenue.

• The proposed talc ovarian-litigation settlement is conditional on participation by at least 95% of remaining claims and excludes mesothelioma cases. The charge therefore does not establish a comprehensive end to talc litigation.

Key Financial Highlights

• Earnings comparability: The current 9M period included $6.1B of litigation expense, while the prior period benefited from an ≈$7.0B talc reserve reversal. The earnings decline is therefore much larger than the change in commercial performance.
• Segment profitability: Innovative Medicine absorbed acquired research, the Sail option premium and higher amortization. MedTech incurred $400M of Orthopaedics separation costs and ≈$300M of PreCardia impairment, partly offset by ≈$200M of tariff recoveries.
• Cash conversion: 9M FCF was $15.1B after $3.73B of capital expenditures. Accrued litigation and noncash charges depressed earnings, while a $2.9B increase in receivables and inventories consumed cash.
• Capital returns: Dividends of $9.59B and repurchases of $5.96B together exceeded FCF. Net shares outstanding were broadly unchanged at ≈2.41B, so repurchases did not materially shrink the share count.

Risk Assessment

• Talc resolution: The reserve’s present value was ≈$9.0B, about half current, and ≈76,500 U.S. plaintiffs had direct claims; settlement conditions and excluded cases leave potential for further charges and cash demands.
• Product exclusivity: STELARA’s decline demonstrates the exposure, while potential 2027 generic entrants for UPTRAVI, OPSUMIT and XARELTO could erode additional sales and related asset values.
• Acquired-asset exposure: Goodwill and net intangible assets totaled $95.1B, exceeding shareholders’ equity of $81.5B; development failures or weaker commercial prospects could trigger further impairments.
• Pricing pressure: China procurement already hurt Surgery, while U.S. pricing and reimbursement changes could constrain the revenue gained from successful medicines.

No risk-factor section was found in this 10-Q. A 10-Q does not have to restate the risk factors in the annual report. Full list: FY2025 10-K.

What to Watch

• Replacement medicines: TREMFYA, oncology and neuroscience currently offset STELARA erosion. Sustained growth across these products would validate the portfolio transition; slowing launches alongside further exclusivity losses would weaken it.
• MedTech execution: Management targets the Orthopaedics separation for mid-2027 while Surgery sales are declining. An orderly separation and stronger remaining franchises would support the reshaping; delays, further impairments or continued Surgery weakness would undermine it.
• Talc settlement: Later filings should establish whether the participation condition is met and how payments develop. Completion would reduce ovarian-claim uncertainty; failure or rising excluded claims could require additional reserves.
• Cash after obligations: Capital returns already exceeded 9M FCF. Future filings will show whether operating cash can fund investment, distributions and litigation payments without sustained additional borrowing.

Not present in this filing: Part II Item 1A, Risk Factors.